Πλοήγηση ανά Θέμα "MODIFYING ANTIRHEUMATIC DRUGS"

Αποτελέσματα 1-2 από 2

FCGR polymorphisms in the treatment of rheumatoid arthritis with Fc-containing TNF inhibitors

Montes, A.; Perez-Pampin, E.; Joven, B.; Carreira, P.; Fernandez-Nebro, A.; Ordonez, M. D.; Navarro-Sarabia, F.; Moreira, V.; Vasilopoulos, Y.; Sarafidou, T.; Caliz, R.; Ferrer, M. A.; Canete, J. D.; de la Serna, A. R.; Magallares, B.; Narvaez, J.; Gomez-Reino, J. J.; Gonzalez, A. (2015)

Objectives: Reproducible association of a functional polymorphism in FCGR2A with response to a TNF inhibitor (TNFi) in patients with rheumatoid arthritis (RA) led us to explore other Fc gamma R functional polymorphisms. ...
Infliximab and Methotrexate in the Treatment of Rheumatoid Arthritis: A Systematic Review and Meta-Analysis of Dosage Regimens

Zintzaras, E.; Dahabreh, I. J.; Giannouli, S.; Voulgarelis, M.; Moutsopoulos, H. M. (2008)

Background: Because of its long-term effectiveness in clinical practice, methotrexate (MTX) is currently the preferred disease-modifying antirheumatic drug (DMARD) for patients with active rheumatoid arthritis (RA). However, ...